23 unknown. 23 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Unknown 23 |
| Phase 2 | 3 | Unknown 3 |
Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg - Type 2 Diabetes, Dyslipidemias | Phase 1 | Unknown | Hyundai Pharm | 56 | 2024-06-20 | 2024-08-29 |
| A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) SGB-3403, Atorvastatin, Placebo - Hyperlipidemias | Phase 1 | Unknown | Suzhou Sanegene Bio Inc. | 64 | 2024-02-18 | 2024-02-02 |
| A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401 JS401, Placebo - Hyperlipidemia | Phase 1 | Unknown | Shanghai Junshi Bioscience Co., Ltd. | 44 | 2023-08-31 | 2023-09-18 |
| A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants VXX-401, Placebo - Hypercholesterolemia | Phase 1 | Unknown | Vaxxinity, Inc. | 64 | 2023-03-07 | 2023-10-12 |
| Safety and Tolerability of SHR-1918 in Healthy Subjects SHR-1918, SHR-1918 placebo - Hyperlipemia | Phase 1 | Unknown | Beijing Suncadia Pharmaceuticals Co., Ltd | 72 | 2022-06-27 | 2023-07-06 |
| To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers ID140009, ID1803+ID1805 - Dyslipidemias, Hypertension | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 60 | 2022-02-22 | 2022-02-28 |
| Efficacy Assessment of Chinese Herbal Medicine Jiangtang Tiaozhi Recipe Treating Participants With Glucose and Lipid Metabolism Disturbances Jiangtang Tiaozhi recipe, Metformin - Type2 Diabetes, Dyslipidemias | Phase 1 / Phase 2 | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 96 | 2021-12-22 | 2023-09-18 |
| Study to Evaluate the Safety and PK of UI018 administration of UI018, co-administration of UIC201806 and UIC201602 - Hyperlipemia, Mixed | Phase 1 | Unknown | Korea United Pharm. Inc. | 44 | 2021-09-06 | 2021-12-21 |
| Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506 YYC506-T and YYC506-A (phase 1), YYC506 (phase 1), YYC506-T and YYC506-A (phase 2) - Dyslipidemias | Phase 1 | Unknown | Yooyoung Pharmaceutical Co., Ltd. | 60 | 2021-01-07 | 2021-05-05 |
| To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults ID1803, ID1801, ID1803+ID1801 - Hypertension, Dyslipidemias | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 30 | 2020-02-01 | 2019-12-26 |
| Supplementation of Oil Palm Phenolics to Healthy Participants Placebos, Oil Palm Phenolics - Cardiovascular Diseases, Hyperlipidemias | Phase 1 | Unknown | National University of Malaysia | 100 | 2019-12-16 | 2019-12-23 |
| A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers CKD-386 formulation 1, CKD-386 formulation 2, D326, D337 and D013 - Hypertension, Dyslipidemias | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 30 | 2019-04-01 | 2019-04-19 |
| BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination. Monolayer group, Bilayer group - Diabetes Mellitus, Type 2, Dyslipidemias | Phase 1 | Unknown | LG Chem | 48 | 2019-03-21 | 2019-03-08 |
| Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults CKD-333, formula I, CKD-333, formula II, CKD-330, D090 - Hypertension, Dyslipidemias | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 36 | 2019-02-25 | 2019-02-22 |
| A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects Sequence 1, Sequence 2, Sequence 3 - Dyslipidemias, Hypertension | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 30 | 2018-08-31 | 2018-11-01 |
| Phase I Drug-drug Interaction of Omega-3 and Atorvastatin Omacor, Pritor, Omacor + Pritor - Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Unknown | DongKoo Bio & Pharma | 48 | 2018-02-01 | 2018-02-22 |
| DP-R212 Pharmacokinetic Study Amlodipine, Rosuvastatin - Hypertension, Hyperlipidemias | Phase 1 | Unknown | Alvogen Korea | 38 | 2016-05-01 | 2016-06-03 |
| Cilostazol-Simvastatin Drug Interaction Study Simvastatin, Pravastatin, Cilostazol - Dyslipidemias, Peripheral Artery Disease | Phase 1 | Unknown | Ajou University School of Medicine | 20 | 2015-04-01 | 2015-05-01 |
| Safety Study of Bile Acid to Treat Hypercholesteremia AHRO-001 - Hypercholesterolemia | Phase 1 | Unknown | AtheroNova Inc. | 110 | 2013-06-01 | 2014-11-20 |
| Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors vegetable - Hypertension, Hypercholesterolemia | Phase 1 | Unknown | University of Guelph | 60 | 2012-04-01 | 2016-10-26 |
Showing 20 of 23. Sign in to see all of them.
Hyperlipidemias (9) · Hypertension (8) · Hypercholesterolemia (5) · Diabetes Mellitus, Type 2 (4) · Atherosclerosis (3) · Cardiovascular Diseases (2) · Coronary Artery Disease (1) · Gyrate Atrophy (1) · Hyperglycemia (1) · Hyperlipoproteinemia Type V (1) · Hypertriglyceridemia (1) · Inflammation (1) · Insulin Resistance (1) · Metabolic Syndrome (1)
Lipid Metabolism Disorders (23) · Metabolic Diseases (23) · Nutritional and Metabolic Diseases (23) · Vascular Diseases (11) · Cardiovascular Diseases (10) · Glucose Metabolism Disorders (5) · Arterial Occlusive Diseases (4) · Arteriosclerosis (4) · Diabetes Mellitus (4) · Endocrine System Diseases (4) · Hyperlipidemias (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Pathological Conditions, Signs and Symptoms (2)
Rosuvastatin Calcium (2) · Amlodipine (1) · Atorvastatin (1) · Cilostazol (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Ezetimibe (1) · Heart Disease Risk Factors (1) · Metformin (1) · Omacor (1) · Pravastatin (1) · Simvastatin (1) · Telmisartan (1) · Vegetables (1) · empagliflozin (1)
Chong Kun Dang Pharmaceutical (3) · IlDong Pharmaceutical Co Ltd (2) · Ajou University School of Medicine (1) · Alvogen Korea (1) · AtheroNova Inc. (1) · Beijing Suncadia Pharmaceuticals Co., Ltd (1) · Caroline Medical Group (1) · DongKoo Bio & Pharma (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Hyundai Pharm (1) · Instituto de Cardiologia do Rio Grande do Sul (1) · Korea United Pharm. Inc. (1) · LG Chem (1) · Logan College of Chiropractic (1) · National University of Malaysia (1)
South Korea (10) · China (3) · Canada (2) · Australia (1) · Brazil (1) · Malaysia (1) · Russia (1) · United States (1)
Dongseong Shin, M.D, Ph.D (1) · Doo-Yeoun Cho, MD (1) · Hyeong-Seok Lim, M.D., Ph.D. (1) · Injin Jang, Dr. (1) · Isa Naina Mohamed, MD, PhD (1) · Jiaxing Tian, PhD (1) · Mark K. Wedel, MD (1) · Michael Mills, MD CCFP (1) · Min Kyu Park, MD (1) · Min Kyu Park, PhD (1) · Sasha Rumyantsev (1) · Seunghun Han, Ph.D. (1)